<DOC>
	<DOC>NCT01583647</DOC>
	<brief_summary>The purpose of this study is to determine the pharmacokinetics of laropiprant following administration of a single dose of 1 (Panel A) and 2 (Panel B) combination tablets of MK-0524A in adolescents with heterozygous familial hypercholesterolemia.</brief_summary>
	<brief_title>A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Postpubescent adolescent age 10 to 16 with heterozygous familial hypercholesterolemia Agree to use (and/or have their partner use) acceptable methods of birth control beginning at the prestudy visit until at least 2 weeks after dosing of study drug Height and weight fall between the 10th and 95th percentile for age with a minimum body weight of 23 kg Receiving appropriate medical care for hypercholesterolemia, such as a statin or other lipidmodifying therapy. History of psychiatric or personality disorders that may affect the patient's ability to participate History of stroke, chronic seizures, or major neurological disorder History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases (excluding lipid abnormalities) Poorly controlled or recently diagnosed Type 1 or Type 2 diabetes mellitus History of neoplastic disease within previous 5 years Consumes alcohol or excessive amounts of products that contain caffeine (e.g. cola) Has had major surgery, donated and/or received blood within previous 8 weeks Participated in another investigational study within previous 4 weeks History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food Positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV) Cannot swallow large tablets Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>